<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200608047684N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-07-30</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Efficacy of Ketamine on Acute Pain</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the Efficacy of Fentanyl Versus Subdissociative-dose Ketamine with Haloperidol on Acute Pain in Adult Patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-07-31</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>200</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/48723</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants divided in two groups randomly by a statistics specialist with Block Stratified Randomization Windows version 6.0.  Each day five participants from those two groups will involved and they will be ordered randomlly .Every morning a person not involved in the study or patient care prepared study packages, and stored them in a locked drawer. When each new subject was enrolled by an attending emergency physician, they were allocated to the next number based on the randomizationschedule. The physician then picked up the matched, numbered package from the drawer, Blinding description: In this research participants aren't informed about the adiministrated medication.Due to the similar appearance of the drugs, the syringes are not covered and according to the information given to the patient, distilled water will be injected instead of haloperidol for patients in the control group (fentanyl). Regarding the side effects described to the patient in informed consent, no information was given about the potential for pain relief of the drugs. For blinding, researcher who chooses patients to participate in research, person who administrates the medications and observer who observes and documents participant's pain are separated persons.</study_design>
      <phase>3</phase>
      <hc_freetext>Acute pain.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: patients with acute pain that treated with 0.3 mg/kg interavenous Ketamine and 2.5 mg interavenous Haloperidol. 2.5 mg Haloperidol diluted with distilled water up to 5ml will be injected by 5ml syringe in one minute through IV line .then immediately the calculated dosage of Ketamine will be diluted by distilled water up to 10ml and will be injected by 10ml syringe in two minutes through same IV line. Intervention 2: Intervention group: patients with acute pain that treated with 1 μg/kg interavenous Fentanyl. In this group first 5ml distilled water will be injected through IV line in one minute insted of Haloperidol then the calculated amount of Fentanyl will be diluted with distilled water up to 10ml and will be injected by 10ml syringe in two minutes through IV line.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All collected data will be available

When:
6 months afer publication

To whom:
Data will be available for Academic researchers and scientists

Conditions:
Statistical analysis of data

Where to obtain:
contact
M.mobin.moradi@gmail.com

How to obtain:
After receiving the application, the requested information will be provided within one month

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Mobin Moradi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 63, Saduqi Ave, Jamalzadeh St</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۴۱۸۶۱۳۷۴۱</zip>
        <telephone>+98 21 6691 0317</telephone>
        <email>m.mobin.moradi@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Pooya Payandemehr</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imama khomeini St. Hasan abad Sq</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1136746911</zip>
        <telephone>+98 21 6634 8500</telephone>
        <email>pooya_mehr@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Any adult patient (age&gt;18) with acute pain who need analgesia</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pain score ≤5
Pregnancy and post-partum women
Altered mental status
Allergy to ketamine or fentanyl
Body weight ≤ 46 kg or ≥ 115
Unstable vital signs: BP≤ 90 mmHg or ≥ 180 mmHg , PR≥150 or ≤50 bits/min , RR≤10 or ≥30
History of recent head or eye trauma
History of Siesure
History of elevated ICP
Chronic pain
Renal or hepatic failure
Substance or alcohol abuse
Documented psychiatric disorders
Opium addiction
Recent use of narcotic analgesics</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G89.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Acute pain, not elsewhere classified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: patients with acute pain that treated with 0.3 mg/kg interavenous Ketamine and 2.5 mg interavenous Haloperidol. 2.5 mg Haloperidol diluted with distilled water up to 5ml will be injected by 5ml syringe in one minute through IV line .then immediately the calculated dosage of Ketamine will be diluted by distilled water up to 10ml and will be injected by 10ml syringe in two minutes through same IV line.</i_keyword>
      <i_keyword>Intervention group: patients with acute pain that treated with 1 μg/kg interavenous Fentanyl. In this group first 5ml distilled water will be injected through IV line in one minute insted of Haloperidol then the calculated amount of Fentanyl will be diluted with distilled water up to 10ml and will be injected by 10ml syringe in two minutes through IV line</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain score by Verbal Numerical Rating Scale (VNRS). Timepoint: 5,10,15 and 30 minutes after administration of medications. Method of measurement: Verbal Numerical Rating Scale (VNRS).</prim_outcome>
      <prim_outcome>Blood pressure. Timepoint: 5,10,15 and 30 minutes after administration of medications. Method of measurement: Sphygmomanometer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Agitation scale calculating with Richmond Agitation-Sedation Scale. Timepoint: When agitation appears. Method of measurement: Richmond Agitation-Sedation Scale.</sec_outcome>
      <sec_outcome>Need for rescue analgesic. Timepoint: 10 minutes after administration of medications. Method of measurement: Asking from patient about presence of pain.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-11-20</approval_date>
        <contact_name>Ethics committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>No. 63, Saduqi Ave., Jamalzadeh St Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
